Overview
Status
Active
Registry date
2023-04-11
Share capital
100,000.00 PLN
Registered address
ul. Wyciszona 3/3, 02-757 Warszawa, Poland
Electronic delivery address
AE:PL-15247-60224-TFUUE-27
Financials
Revenue history (in k)
Filing timeliness
3 of 3 financial statements were filed late (the longest delay 533 days for 2023).
- 202515/10/2026
- 202430/12/2025
- 202330/12/2025
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 1.56mMedianUSD 1.06mAverageUSD 22.40m
Net profit
This companyUSD 613.53kMedianUSD 37.33kAverageUSD 880.24k
Operating costs
This companyUSD 874.37kMedianUSD 922.77kAverageUSD 21.08m
Assets
This companyUSD 1.77mMedianUSD 608.93kAverageUSD 11.85m
Industry
Authorized Representatives
Egor Fiodarau – President of the Management Board
Manner of representation
Each member of the management board is authorized to make declarations on behalf of the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Egor Fiodarauage 28 | 90 | $24,311.18 | 90% |
Anna Fiodaravaage 66 | 10 | $2,701.24 | 10% |
The articles of association place no restrictions on share transfers.
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2023-04-18.
Debt
No entries in the National Debtors Register (KRZ).
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Brandexsp. z o.o. | $1,958,619.75 | brandex.pl | ||
| PUBE Globalsp. z o.o. | $1,777,827.09 | pubeglobal.com | ||
| Totis Pharmasp. z o.o. | $1,777,307.47 | totispharma.com | ||
| Tricopat Globalsp. z o.o. | $1,772,824.41 | tricopatglobal.com | ||
| New Nordic Healthbrands Polskasp. z o.o. | $1,677,813.61 | newnordic.pl | ||
| Farmedicasp. z o.o. | $1,689,796.86 | farmedica.pl | ||
| Phytopur Biosp. z o.o. | $1,672,156.55 | phytopurbio.pl | ||
| DEEP Pharmasp. z o.o. | $1,664,192.79 | deeppharma.pl | ||
| Novicaresp. z o.o. | $1,512,398.66 | novicare.pl | ||
| Dermaprofilsp. z o.o. | $1,431,262.08 | dermaprofil.pl |
FAQ
The main business activity of Octerium focuses on wholesale of pharmaceutical goods.
The company was registered in the Polish National Court Register (KRS) on April 11, 2023.
The headquarters is located at: ul. Wyciszona 3, 02-757 Warszawa.
The share capital of the company is PLN 100,000 (approx. $27,012).
The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.
The company reported a revenue of USD 1,570,957 in 2024, which is an increase of 90.6% compared to 2023.
Yes, in 2024 the company was profitable, achieving a net profit of USD 597,904, meaning the company increased its profit by 159.9%.
The largest operating cost category falls under other operating costs. This category amounted to USD 871,819 in 2024, representing 97% of all operating expenses.
Last updated: 2026-10-16
